Syros Pharmaceuticals (NASDAQ:SYRS) Given Daily Media Impact Score of 0.07

Media stories about Syros Pharmaceuticals (NASDAQ:SYRS) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Syros Pharmaceuticals earned a news impact score of 0.07 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.5862742120408 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the media stories that may have impacted Accern Sentiment’s analysis:

Syros Pharmaceuticals (NASDAQ:SYRS) opened at 21.81 on Friday. Syros Pharmaceuticals has a 52-week low of $8.50 and a 52-week high of $24.38. The firm’s market capitalization is $572.73 million. The firm’s 50-day moving average is $19.45 and its 200-day moving average is $15.40.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Wednesday, August 9th. The company reported ($0.52) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.03. On average, equities analysts expect that Syros Pharmaceuticals will post ($2.09) earnings per share for the current year.

Several brokerages recently issued reports on SYRS. JMP Securities downgraded shares of Syros Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday. Wedbush reiterated an “outperform” rating and set a $22.84 price target (down previously from $25.00) on shares of Syros Pharmaceuticals in a research report on Thursday. Cowen and Company reiterated a “buy” rating on shares of Syros Pharmaceuticals in a research report on Wednesday. Zacks Investment Research downgraded shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Finally, ValuEngine upgraded shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company. Syros Pharmaceuticals has an average rating of “Buy” and a consensus price target of $20.81.

ILLEGAL ACTIVITY NOTICE: “Syros Pharmaceuticals (NASDAQ:SYRS) Given Daily Media Impact Score of 0.07” was first published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/08/12/syros-pharmaceuticals-nasdaqsyrs-receiving-somewhat-favorable-media-coverage-accern-reports-updated.html.

In related news, insider Eric R. Olson sold 2,500 shares of Syros Pharmaceuticals stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $23.59, for a total value of $58,975.00. Following the transaction, the insider now directly owns 2,500 shares of the company’s stock, valued at $58,975. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Richard A. Young sold 3,282 shares of Syros Pharmaceuticals stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $22.09, for a total value of $72,499.38. Following the completion of the transaction, the director now directly owns 423,383 shares in the company, valued at $9,352,530.47. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 18,282 shares of company stock worth $404,599.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

What are top analysts saying about Syros Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Syros Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit